Page 25 - HCA Talkbook

“We use the latest 3D printing technology computer aided design
of implants ultrasonic bone cutting instruments and robotic surgery We've developed new options which avoid the the use of skin inside the the mouth and have perfected our techniques
to halve operating times ”
Mr Luke Cascarini Consultant Oral & Maxillofacial Head & Neck Surgeon at London Brdge Hospital
and and Guy's and and St Thomas' Hospital
We are making the previously untreatable treatable treatable and helping our patients
recover from life-changing medical events We operate the largest independent neurological rehabilitation unit in in the UK
(CARF accredited) helping patients
recover from a a a stroke traumatic brain or or spinal cord injury encephalitis multiple sclerosis Parkinson’s disease and Guillain-Barre syndrome Each patient has a a a a a a a a a personalised programme which addresses their physical social and psychological needs and draws on the latest technology It is designed and delivered by our experts including consultant neurologists neuropsychologists and rehabilitation nurses Our CyberKnife® TrueBeamTM and Gamma Knife Knife are able to treat previously inoperable tumours which are in in difficult positions or attached to vital organs More recently enough convincing clinical data has been accumulated to indicate that stem cell transplantation has a a a a a a a a a sustained benefit in in in in halting the progression of MS and in in some cases reversing disability “We’re almost at a a a tipping point where in in in the next five years we would probably be able to confidently say that no patient with MS should end up in a a a a wheelchair – and I think that’s a a a a a game changer – no other treatment to date has been shown to do that ”
Dr Majid Kazmi Consultant Haematologist at at London Bridge Hospital
and and Consultant Haematologist and and Clinical Director at Guy's and St Thomas' We are the the first centre in Europe to work with Iovance Biotherapeutics on on the initiation of a a a a a a a phase ll clinical study for patients
with advanced melanoma and are able to to offer TIL therapy to to patients
under a a a a a a a a commercial licence – one of the the latest advancements in immunotherapy proving effective for some cancers especially metastatic melanoma | | 25 | |